Prognose
Analytikernes gennemsnitlige kursmål er 1,82 € (+127,50 %). Medianen er 1,82 € (+127,50 %).
| Køb |
8 |
| Behold |
6 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Cardiff Oncology outlines phase III plan for Onvansertib, financing open
Cardiff Oncology confirmed exclusive worldwide rights to Onvansertib after an agreement with Nerviano and presented convincing phase II data at an investor conference, reporting an overall response rate of 72% for the Onvansertib plus FOLFIRI/Bevacizumab combination. The FDA agreed to a simplified 1:1 randomized phase III design (CRDF‑004) with about 640 patients, with overall response rate as the primary endpoint potentially enabling accelerated approval. The company is targeting a global launch in early 2026 but still needs to secure $128–176 million to fund the trial and is weighing capital‑markets options, non‑dilutive financings and partnerships. » Mere på de.investing.com
Cardiff Oncology secures $10 million in registered direct offering
Cardiff Oncology completed the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 each in a registered direct offering, yielding gross proceeds of approximately $10 million before fees. Officers and directors purchased 731,707 shares and warrants at $1.435 each; the warrants have an exercise price of $1.31, are exercisable no earlier than six months after issuance or after approval of the equity increase, and expire five and a half years after they first become exercisable. H.C. Wainwright & Co. acted as exclusive placement agent. Cardiff Oncology intends to use the net proceeds for working capital and general corporate purposes. » Mere på de.investing.com
Cardiff Oncology presents preclinical Onvansertib data at AACR meeting
Cardiff Oncology will present preclinical data on its PLK1 inhibitor Onvansertib at the AACR 2026 annual meeting, which are intended to show that Onvansertib enhances the antitumor activity of trastuzumab‑deruxtecan (T‑DXd) and overcomes resistance in treatment‑refractory HER2‑low breast cancer models. Onvansertib is an orally administered PLK1 inhibitor currently being tested in a phase 2 trial in RAS‑mutant metastatic colorectal cancer and is being investigated in additional trials across various tumor types. The poster (abstract no. 329) will be made available on the company’s website after the presentation. » Mere på de.investing.com
Cardiff Oncology presents strong phase‑2 data for onvansertib in RAS‑mutant colorectal cancer
Onvansertib, combined with FOLFIRI and bevacizumab, showed an overall response rate of 72.2%, well above the 42% benchmark. Cardiff plans a global phase‑3 trial at 30 mg in the first half of 2026, subject to discussions with the FDA. The company has $58.3 million in cash, which is expected to fund operations until early 2027 but does not cover the anticipated costs of the phase‑3 trial. Pfizer invested $15 million and is serving as a CRO partner; Cardiff retains full rights to the program, is exploring additional indications, and anticipates regulatory and financial challenges. » Mere på de.investing.com
Cardiff Oncology stock plunges after phase 2 update on Onvansertib
Cardiff Oncology reported that Onvansertib combined with FOLFIRI/Bevacizumab showed dose-dependent higher overall response rates; the 30 mg group achieved a confirmed ORR of 72.2% versus 43.2% with standard therapy, and progression-free survival has not yet been reached. Despite the positive assessment and the announcement to advance the 30 mg dose into a registrational trial, shares fell about 30% in premarket trading — investors appeared disappointed, apparently due to expectations of stronger signals or concerns about statistical significance. Onvansertib was well tolerated; the most common adverse event was neutropenia. The company appointed an interim CEO and announced personnel changes in finance, and said it will present final data and a plan for the registrational study in H1 2026 in coordination with the FDA. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Cardiff Oncology en omsætning på 150,97 t € og et nettoresultat på -7,82 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 150,97 t | 47,64 % |
| Bruttofortjeneste | -8,14 mio. | 8.059,46 % |
| Nettoresultat | -7,82 mio. | 18,49 % |
| EBITDA | -7,74 mio. | 15,60 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 59,4 mio. € |
Antal aktier | 77,8 mio. |
Højeste/laveste i 52 uger | 3,01 € - 0,65 € |
| Udbytte | Nej |
Beta | 1,56 |
P/E (PE Ratio) | -1,53 |
PEG (PEG Ratio) | -0,03 |
K/I (PB Ratio) | 2,27 |
P/S (PS Ratio) | 116,76 |
Virksomhedsprofil
Cardiff Oncology, Inc., et klinisk-stadie onkologiselskab, udvikler lægemiddelbehandlinger til kræftpatienter i Californien. Selskabets førende lægemiddelkandidat er onvansertib, en oral selektiv Polo-like Kinase 1-hæmmer til anti-kræftterapi; CY140, en hæmmer af PLK1, PLK2 og PLK3, der er i fase 1/2-studier for solide tumorer og leukæmier; metastatisk tyktarmskræft, som er i kliniske forsøg; og TROV-054 er en fase 1b/2-undersøgelse for FOLFIRI og bevacizumab. Selskabets TROV-053 er også i et fase II-klinisk forsøg i kombination med Zytiga til metastatisk kastrationsresistent prostatakræft. Selskabet betjener primært farmaceutiske producenter. Selskabet var tidligere kendt som Trovagene, Inc. og skiftede navn til Cardiff Oncology, Inc. i maj 2012. Cardiff Oncology, Inc. blev stiftet i 1999 og har hovedkvarter i San Diego, Californien.
| Navn | Cardiff Oncology |
| CEO | Mani Mohindru |
| Hjemsted | San Diego,
ca USA |
| Websted | |
| Sektor | Dagligvarer |
| Branche | Fødevarer |
| Børsnotering | 27.07.2004 |
| Medarbejdere | 31 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | CRDF |
Frankfurt | XE7C.F |
Düsseldorf | XE7C.DU |
München | XE7C.MU |